Perspectives in vaccine adjuvants for allergen-specific immunotherapy

Immunology Letters

Volumn 161, Issue 2, 2014, Pages 207-210

  Filì, Lucia ^a   Cardilicchia, Elisa ^a   Maggi, Enrico ^a   Parronchi, Paola ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Adjuvants; Allergy; Vaccine

Indexed keywords

ADENINE DERIVATIVE; CPG OLIGONUCLEOTIDE; IMIDAZOQUINOLINE DERIVATIVE; IMMUNOGLOBULIN E; IMMUNOLOGICAL ADJUVANT; OLIGONUCLEOTIDE; PHOSPHORYL LIPID A; PLACEBO; UNCLASSIFIED DRUG; VACCINE; ADENINE; ANTIGEN; CPG-OLIGONUCLEOTIDE; CYTOKINE; LIPID A; OLIGODEOXYRIBONUCLEOTIDE;

ALLERGIC RHINITIS; ALLERGY; ANTIGEN SPECIFICITY; ARTICLE; HUMAN; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; IMMUNOSTIMULATION; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TH1 CELL; TH2 CELL; VACCINATION; ANALOGS AND DERIVATIVES; ANIMAL; DESENSITIZATION; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM;

ADENINE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; HUMANS; IMMUNITY, INNATE; LIPID A; OLIGODEOXYRIBONUCLEOTIDES; TH2 CELLS; VACCINATION;

EID: 84906791237     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.12.011     Document Type: Article

References (49)

1. Romagnani S. Regulation of the development of type 2 T-helper cells in allergy. Curr Opin Immunol 1994, 6(6):838-846.
2. Maggi E., Vultaggio A., Matucci A. T-cell responses during allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol 2012, 12(1):1-6.
3. Lambrecht B.N., Kool M., Willart M.A., Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009, 21(1):23-29.
4. Munford R.S. Sensing gram-negative bacterial lipopolysaccharides: a human disease determinant?. Infect Immun 2008, 76:454-465.
5. Mata-Haro V., Cekic C., Martin M., Chilton P.M., Casella C.R., Mitchell T.C. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007, 316(5831):1628-1632.
6. Okemoto K., Kawasaki K., Hanada K., Miura M., Nishijima M.J. A potent adjuvant monophosphoryl lipid A triggers various immune responses, but not secretion of IL-1beta or activation of caspase-1. Immunology 2006, 176:1203-1208.
7. Drachenberg K.J., Wheeler A.W., Stuebner P., Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001, 56(6):498-505.
8. Patel P., Holdich T., Fischer von Weikersthal-Drachenberg K.J., Huber B. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen. J Allergy Clin Immunol 2013, [Epub ahead of print].
9. Baldrick P., Richardson D., Wheeler A.W. Safety evaluation of a glutaraldehyde modified tyrosine adsorbed house dust mite extract containing monophosphoryl lipid A (MPL) adjuvant: a new allergy vaccine for dust mite allergy. Vaccine 2001, 20(5/6):737-743.
10. Mothes N., Heinzkill M., Drachenberg K.J., Sperr W.R., Krauth M.T., Majlesi Y., et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003, 33(9):1198-1208.
11. Crivellaro M., Senna G.E., Pappacoda A., Vanzelli R., Spacal B., Marchi G., et al. Safety of ultrashort-term SIT with pollen allergoids adjuvanted by monophosphoryl lipid A: a prospective Italian survey. Eur Ann Allergy Clin Immunol 2011, 43(2):58-60.
12. Musarra A., Bignardi D., Troise C., Passalacqua G. Long-lasting effect of a monophosphoryl lipid-adjuvanted immunotherapy to parietaria: a controlled field study. Eur Ann Allergy Clin Immunol 2010, 42(3):115-119.
13. Puggioni F., Durham S.R., Francis J.N. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. Allergy 2005, 60(5):678-684.
14. Tokunaga T., Yamamoto T., Yamamoto S. How BCG led to the discovery of immunostimulatory DNA. Jpn J Infect Dis 1999, 52(1):1-11.
15. Bode C., Zhao G., Steinhagen F., Kinjo T., Klinman D.M. CpG DNA as a vaccine adjuvant. Rev Vaccines 2011, 10(4):499-511.
16. Krieg A.M. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther 2012, 22(2):77-89.
17. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408(6813):740-745.
18. Zhou W., Li Y., Pan X., Gao Y., Li B., Qiu Z., et al. Toll-like receptor 9 interaction with CpG ODN - an in silico analysis approach. Theor Biol Med Model 2013, 10:10-18.
19. Jakob T., Walker P.S., Krieg A.M., von Stebut E., Udey M.C., Vogel J.C. Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses. Int Arch Allergy Immunol 1999, 118(2-4):457-461.
20. Bohle B., Jahn-Schmid B., Maurer D., Kraft D., Ebner C. Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur J Immunol 1999, 29(7):2344-2353.
21. 4+ T cells into Th1 effectors. J Immunol 1999, 163(11):5946-5953.
22. Trujillo-Vargas C.M., Mayer K.D., Bickert T., Palmetshofer A., Grunewald S., Ramirez-Pineda J.R., et al. Vaccinations with T-helper type 1 directing adjuvants have different suppressive effects on the development of allergen-induced T-helper type 2 responses. Clin Exp Allergy 2005, 35(8):1003-1013.
23. Jahn-Schmid B., Wiedermann U., Bohle B., Repa A., Kraft D., Ebner C. Oligodeoxynucleotides containing CpG motifs modulate the allergic TH2 response of BALB/c mice to Bet v 1, the major birch pollen allergen. J Allergy Clin Immunol 1999, 104(5):1015-1023.
24. Kline J.N., Krieg A.M., Waldschmidt T.J., Ballas Z.K., Jain V., Businga T.R. CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. J Allergy Clin Immunol 1999, 104(6):1258-1264.
25. Spiegelberg H.L., Tighe H., Roman M., Broide D., Raz E. Inhibition of IgE formation and allergic inflammation by allergen gene immunization and by CpG motif immunostimulatory oligodeoxynucleotides. Allergy 1998, 53(Suppl. 45):93-97.
26. Hessenberger M., Weiss R., Weinberger E.E., Boehler C., Thalhamer J., Scheiblhofer S. Transcutaneous delivery of CpG-adjuvanted allergen via laser-generated micropores. Vaccine 2013, 31(34):3427-3434.
27. Tighe H., Takabayashi K., Schwartz D., Van Nest G., Tuck S., Eiden J.J., et al. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000, 106(1 (Pt 1)):124-134.
28. Simons F.E., Shikishima Y., Van Nest G., Eiden J.J., HayGlass K.T. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 2004, 113(6):1144-1151.
29. Tulic M.K., Fiset P.O., Christodoulopoulos P., Vaillancourt P., Desrosiers M., Lavigne F., et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004, 113(2):235-241.
30. Creticos P.S., Schroeder J.T., Hamilton R.G., Balcer-Whaley S.L., Khattignavong A.P., Lindblad R., et al. Immunotherapy with a ragweed-Toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006, 355(14):1445-1455.
31. Klimek L., Pfaar O. A comparison of immunotherapy delivery methods for allergen immunotherapy. Expert Rev Clin Immunol 2013, 9(5):465-474.
32. Tomai M.A., Gibson S.J., Imbertson L.M., Miller R.L., Myhre P.E., Reiter M.J., et al. Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antiviral Res 1995, 28(3):253-264.
33. Wagner T.L., Ahonen C.L., Couture A.M., Gibson S.J., Miller R.L., Smith R.M., et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and Imiquimod. Cell Immunol 1999, 191(1):10-19.
34. 4+ TH2 lymphocytes into IFN-gamma-producing cells. J Allergy Clin Immunol 2003, 111(2):380-388.
35. Vasilakos J.P., Tomai M.A. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants. Expert Rev Vaccines 2013, 12(7):809-819.
36. Rajagopal D., Paturel C., Morel Y., Uematsu S., Akira S., Diebold S.S. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood 2010, 115(10):1949-1957.
37. Moisan J., Camateros P., Thuraisingam T., Marion D., Koohsari H., Martin P., et al. TLR7 ligand prevents allergen-induced airway hyperresponsiveness and eosinophilia in allergic asthma by a MyD88-dependent and MK2-independent pathway. Am J Physiol Lung Cell Mol Physiol 2006, 290(5):L987-L995.
38. Drake M.G., Scott G.D., Proskocil B.J., Fryer A.D., Jacoby D.B., Kaufman E.H. Toll-like receptor 7 rapidly relaxes human airways. Am J Respir Crit Care Med 2013, 188(6):664-672.
39. Kaufman E.H., Fryer A.D., Jacoby D.B. Toll-like receptor 7 agonists are potent and rapid bronchodilators in guinea pigs. J Allergy Clin Immunol 2011, 127(2):462-469.
40. Xirakia C., Koltsida O., Stavropoulos A., Thanassopoulou A., Aidinis V., Sideras P., et al. Toll-like receptor 7-triggered immune response in the lung mediates acute and long-lasting suppression of experimental asthma. Am J Respir Crit Care Med 2010, 181(11):1207-1216.
41. Philbin V.J., Dowling D.J., Gallington L.C., Cortés G., Tan Z., Suter E.E., et al. Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. J Allergy Clin Immunol 2012, 130(1):195-204.
42. Shukla N.M., Lewis T.C., Day T.P., Mutz C.A., Ukani R., Hamilton C.D., et al. Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound Toll-like receptor-7 agonistic imidazoquinolines. Bioorg Med Chem Lett 2011, 21(11):3232-3236.
43. Pfaar O., Cazan D., Klimek L., Larenas-Linnemann D., Calderon M.A. Adjuvants for immunotherapy. Curr Opin Allergy Clin Immunol 2012, 12(6):648-657.
44. Hirota K., Kazaoka K., Niimoto I., Kumihara H., Sajiki H., Isobe Y. Discovery of 8-hydroxyadenines as a novel type of interferon inducer. J Med Chem 2002, 45(25):5419-5422.
45. Isobe Y., Tobe M., Ogita H., Kurimoto A., Ogino T., Kawakami H., et al. Synthesis and structure-activity relationships of 2-substituted-8-hydroxyadenine derivatives as orally available interferon inducers without emetic side effects. Bioorg Med Chem 2003, 11(17):3641-3647.
46. Filì L., Ferri S., Guarna F., Sampognaro S., Manuelli C., Liotta F., et al. Redirection of allergen-specific TH2 responses by a modified adenine through Toll-like receptor 7 interaction and IL-12/IFN release. J Allergy Clin Immunol 2006, 118(2):511-517.
47. Filì L., Vultaggio A., Cardilicchia E., Manuelli C., Casini A., Nencini F., et al. A novel allergen-adjuvant conjugate suitable for specific immunotherapy of respiratory allergy. J Allergy Clin Immunol 2013, 132(1):84-92.
48. Vultaggio A., Nencini F., Fitch P.M., Filì L., Maggi L., Fanti P., et al. Modified adenine (9-benzyl-2-butoxy-8-hydroxyadenine) redirects Th2-mediated murine lung inflammation by triggering TLR7. J Immunol 2009, 182(2):880-889.
49. Vultaggio A., Nencini F., Pratesi S., Maggi L., Guarna A., Annunziato F., et al. The TLR7 ligand 9-benzyl-2-butoxy-8-hydroxy adenine inhibits IL-17 response by eliciting IL-10 and IL-10-inducing cytokines. J Immunol 2011, 186(8):4707-4715.